Angiotensin II formation by an alternative pathway during exercise in humans

What Was Tested

The paper reports a study of Angiotensin II, published as a randomized controlled trial.

The researchers postulated a 'kinin-tensin system' in which angiotensin II (Ang II) is cleaved by one or more serine protease independent of renin or angiotensin converting enzyme (ACE).

The aim was to determine whether this alternative Ang II-forming pathway by serine proteases participates in the rise in plasma levels of Ang II during exercise in humans.

Who Took Part

By PubMed's age tags, the people studied were adults, men only.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and crossover study.

Random assignment meant chance, not the researchers, decided who got Angiotensin II and who got the comparison, which limits bias.

Neither the participants nor the staff measuring them knew who was on Angiotensin II, so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Angiotensin II group a baseline to be compared against.

In the crossover set-up each of the participants took both Angiotensin II and the comparison in turn, acting as their own control.

A time span of 3 days appears in the methods.

What Was Measured

Topics PubMed links to this paper include Angiotensin I, Angiotensin II, Benzamidines, Blood Pressure, Bradykinin, Captopril and Exercise.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Angiotensin II over 3 days.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 1994 (Journal of hypertension), a journal based in Netherlands.

More context: the Angiotensin II compound page, all human trials.